Newsroom

Sorted by: Latest

-

FBI Agents Association Statement on 25th Anniversary of 9/11 Terrorist Attacks

WASHINGTON--(BUSINESS WIRE)--In commemoration of the 25th anniversary of the September 11, 2001 terrorist attacks, the FBI Agents Association (FBIAA) issued the following statement:“Today marks a solemn and significant milestone, the 25th anniversary of the terrorist attacks of September 11, 2001. A quarter of a century later, we pause to remember the nearly 3,000 innocent lives lost, honor the extraordinary courage of those who responded, and reflect on the lasting impact of a day that forever...
-

Eutelsat and Grupo W Com Expand Long-Term Partnership to Advance Next-Gen Television Services in Mexico

PARIS--(BUSINESS WIRE)--Eutelsat and Grupo W Com Expand Long-Term Partnership to Advance Next-Gen Television Services in Mexico...
-

Qube Research & Technologies LTD UK Regulatory Announcement: Form 8.3

LONDON--(BUSINESS WIRE)--  Ap27 FORM 8.3 IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION (a) Full name of discloser Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a) The naming of nominee or vehicle companies is insufficient. For...
-

AEVEX Announces Multi-Year Marketing Partnership with the Washington Commanders

SOLANA BEACH, Calif.--(BUSINESS WIRE)--AEVEX Corp. (NYSE: AVEX), a leading U.S. defense technology company delivering autonomous unmanned systems, AI-enabled mission software, mission support capabilities and advanced intelligence, surveillance, reconnaissance solutions, today announced a multi-year marketing partnership with the Washington Commanders. Beginning with the 2026 NFL season, AEVEX will become a Proud Partner of the Washington Commanders, establishing a significant new brand presenc...
-

Tempus Launches Effort to Build the Largest Multimodal Whole-Genome Dataset to Advance AI-Driven Healthcare Innovation

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced an initiative to build a research platform containing 100,000 whole genomes linked to longitudinal clinical information over the next several years. The effort will create the first de-identified multimodal whole-genome sequencing (WGS) dataset built around disease populations and patient outcomes, specifically optimized for AI-driven research. Once this dataset is complete, Tempus plans to expand the effort with the goal o...
-

Dynex Capital, Inc. Declares Common and Preferred Stock Dividends

GLEN ALLEN, Va.--(BUSINESS WIRE)--Dynex Capital, Inc. (NYSE: DX; “Dynex” or the “Company”), a REIT with a long track record of generating dividends from high-quality mortgage assets, announced today that the Company’s Board of Directors has declared a cash dividend of $0.17 per share on its Common Stock for September 2026. The Common dividend is payable on October 1, 2026 to shareholders of record as of September 21, 2026.The Company’s Board also declared a quarterly cash dividend of $0.60793 pe...
-

Qube Research & Technologies LTD UK Regulatory Announcement: Form 8.3

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-

Qube Research & Technologies LTD UK Regulatory Announcement: Form 8.3

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-

Qube Research & Technologies LTD UK Regulatory Announcement: Form 8.3

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-

Aptar Pharma Expands Preservative Free Technology Production in Latin America

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Pharma expands Advanced Preservative Free pump production to Argentina; strengthens local manufacturing & supply for Latin American customers....